Comparative Pharmacology
Head-to-head clinical analysis: SYMMETREL versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYMMETREL versus VEKLURY.
SYMMETREL vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits influenza A virus uncoating and viral RNA replication; increases dopamine release and blocks dopamine reuptake in the CNS.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
100 mg orally twice daily; may increase to 200 mg orally twice daily if tolerated, usually in divided doses. For Parkinson's disease, 100 mg orally twice daily; for drug-induced extrapyramidal reactions, 100 mg orally twice daily.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal half-life: 24-48 hours (young adults); 48-72 hours (elderly); may extend to 7-10 days in severe renal impairment. Clinically, steady-state achieved in 4-7 days.
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Primarily renal excretion (90-95% unchanged) via glomerular filtration and tubular secretion; minor fecal (<5%). Dose adjustment required in renal impairment.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category C
Category C
Antiviral and Antiparkinsonian
Antiviral